Loading...
XNAS:XAIR
BEYOND AIR, INC. shares are trading lower after the company updated its fiscal year 2026 revenue guidance to $8 to $10 million, amidst increased debt financing and existing financial losses.
Beyond Air shares are trading lower after the company announced the exercise of warrants for $3.25 million, introducing new unregistered warrants.
Beyond Air shares are trading higher after its subsidiary NeuroNOS received FDA Orphan Drug Designation for their investigational glioblastoma treatment, BA-101.
Beyond Air shares are trading lower after the company reported a net loss of $46.6 million for the fiscal year, with cost of revenue exceeding revenue due to device depreciation and upgrade costs.
Beyond Air shares are trading higher after its subsidiary NeuroNOS received FDA Orphan Drug Designation for BA-102, a treatment for Phelan-McDermid Syndrome linked to Autism.